Current Report Filing (8-k)
April 14 2015 - 2:56PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): April 7, 2015
RICH
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
NEVADA |
|
000-54767 |
|
46-3259117 |
(State
or other jurisdiction of
incorporation
or organization) |
|
Commission
file number |
|
(IRS
Employer
Identification
No.) |
9595
Wilshire Blvd, Suite 900
Beverly
Hills, CA 90212
(Address
of principal executive offices)
(323)
424-3169
(Registrant’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] |
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item
3.02 Unregistered
Sales of Equity Securities
On
March 30, 2015, the Company issued 18,181,818 shares of Company common stock to satisfy the conversion of $10,000 of a previously
issued convertible note payable with Typenex Co-Investment LLC.
On
April 2, 2015, the Company issued 41,111,111 shares of Company common stock to satisfy the conversion of $16,650.00 of a previously
issued convertible note payable with Auctus Private Equity Fund LLC.
On
April 7, 2015, the Company issued 20,964,361 shares of Company common stock to satisfy the conversion of $10,000 of a previously
issued convertible note payable with Typenex Co-Investment LLC.
On
April 8, 2015, the Company issued 45,454,545 shares of Company common stock to satisfy the conversion of $20,000.00 of a previously
issued convertible note payable with KBM Worldwide Inc.
On
April 8, 2015, the Company issued 45,356,111 shares of Company common stock to satisfy the conversion of $15,307.69 of a previously
issued convertible note payable with Auctus Private Equity Fund LLC.
On
April 9, 2015, the Company issued 32,545,455 shares of Company common stock to satisfy the conversion of $14,320 of a previously
issued convertible note payable with KBM Worldwide Inc.
The
issuances of the above referenced shares were made in reliance on the exemption provided by Section 4(2) of the Securities Act
for the offer and sale of securities not involving a public offering. The Company's reliance upon Section 4(2) of the Securities
Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private
transaction by us which did not involve a public offering; (b) there was only a one investor who was an accredited investor; (c)
there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down
into smaller denominations; and (e) the issuance of shares was pursuant to a convertible note payable which was negotiated directly
between the investor and the Company.
The
total number of outstanding shares of common stock of the Company as of April 9, 2015 after the above described issuance is 1,732,515,540.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
RICH
PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
|
Dated:
April 13, 2015 |
|
|
|
By: |
|
/s/ Ben
Chang |
|
|
|
|
|
|
|
|
Ben
Chang
Chief
Executive Officer |